Patent
Gene signatures for the prediction of prostate cancer recurrence
| العنوان: | Gene signatures for the prediction of prostate cancer recurrence |
|---|---|
| Patent Number: | 12180,550 |
| تاريخ النشر: | December 31, 2024 |
| Appl. No: | 17/292748 |
| Application Filed: | November 08, 2019 |
| مستخلص: | Disclosed are gene signatures and methods for predicting the recurrence of prostate cancer in prostatectomized subjects. Other objectives of the invention are assay devices and kits for determining the expression levels of specific gene sets correlated to prostate cancer recurrence. |
| Inventors: | BRACCO IMAGING S.P.A. (Milan, IT) |
| Assignees: | BRACCO IMAGING S.P.A. (Milan, IT) |
| Claim: | 1. An assay device comprising an array consisting of multiple polynucleotide probes complementary and/or hybridizable to the mRNAs of ACADVL, CARHSP1, CNTNAP1, DNASE1L2, RNF103, SEZ6L, SLC22A6, UGGT2, WDR52, and optionally one or more selected from ATP5D, C14orf109, CCDC144A, CDH15, CELSR3, DDX5, EHD4, EPHB3, LOC100508936, PABPC1, PIP4K2C, and PLCG1 genes, wherein the multiple polynucleotide probes are immobilized on a solid support. |
| Claim: | 2. The assay device according to claim 1 , wherein said multiple polynucleotide probes are complementary and/or hybridizable to the mRNAs of ACADVL, CARHSP1, CNTNAP1, DNASE1L2, RNF103, SEZ6L, SLC22A6, UGGT2, and WDR52 genes. |
| Claim: | 3. The assay device according to claim 1 , wherein said multiple polynucleotide probes are consist of sequences complementary and/or hybridizable to the mRNAs of ACADVL, CARHSP1, CCDC144A, CNTNAP1, DDX5, DNASE1L2, EHD4, PIP4K2C, RNF103, SEZ6L, SLC22A6, UGGT2, and WDR52 genes. |
| Claim: | 4. The assay device according to claim 1 , wherein said multiple polynucleotide probes are complementary and/or hybridizable to the mRNAs of ACADVL, C14orf109, CARHSP1, CCDC144A, CDH15, CELSR3, CNTNAP1, DDX5, DNASEIL2, EHD4, PABPC1, PIP4K2C, RNF103, SEZ6L, SLC22A6, UGGT2, and WDR52 genes. |
| Claim: | 5. The assay device according to claim 1 , wherein said multiple polynucleotide probes are complementary and/or hybridizable to the mRNAs of ACADVL, ATP5D, C14orf109, CARHSP1, CCDC144A, CDH15, CELSR3, CNTNAP1, DDX5, DNASE1L2, EHD4, EPHB3, LOC100508936, PABPC1, PIP4K2C, PLCG1, RNF103, SEZ6L, SLC22A6, UGGT2, and WDR52 genes. |
| Claim: | 6. The assay device according to claim 1 , wherein the array is a microarray and the multiple polynucleotide probes are immobilized on a solid glass substrate or membrane in separate locations or spots. |
| Claim: | 7. A kit containing the assay device according to claim 1 and at least one reagent. |
| Claim: | 8. The kit according to claim 7 , wherein the reagent comprises a labeled primer, a nucleotide, or a combination thereof. |
| Claim: | 9. The kit according to claim 8 , wherein the reagent comprises biotin labeled dNTPs. |
| Claim: | 10. The kit according to claim 7 , further comprising at least one enzyme. |
| Claim: | 11. The kit according to claim 10 , wherein the at least one enzyme comprises a reverse transcriptase. |
| Patent References Cited: | 2001/0053519 December 2001 Fodor 2008121132 October 2008 2010056993 May 2010 2012006447 January 2012 2013185779 December 2013 |
| Other References: | GeneAnnot. Retrieved on Feb. 29, 2024 from the internet: https://genecards.weizmann.ac.il/geneannot/index.shtml. (Year: 2024). cited by examiner “Affymetrix GeneChip Human Genome U133 Array Set HG-UI33A,” Gene Expression Omnibus (GEO) depository, available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL96 (2002). cited by applicant Barrett, T, et al. “NCBI GEO: mining tens of millions of expression profiles—database and tools update,” Nucleic Acids Res., 35:D760-D765 (2007). cited by applicant Bettuzzi, S, et al. “Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study,” Cancer Res. 63(13):3469-72 (2003). cited by applicant Bismar, TA, et al. “Defining aggressive prostate cancer using a 12-gene model,” Neoplasia, 8:59-68 (2006). cited by applicant Carroll, P, et al. “Prostate Cancer Early Detection, version 2.2015,” Journal of the National Comprehensive Cancer Network, 13(12):1534-1561 (2015). cited by applicant Chen, X, et al. “An Accurate Prostate Cancer Prognosticator Using a Seven-Gene Signature Plus Gleason Score and Taking Cell Type Heterogeneity into Account,” PLoS One, 7(9): e45178 (2012). cited by applicant Glinsky, GV et al. “Gene expression profiling predicts clinical outcome of prostate cancer,” J Clin Invest., 113 (6):913-23 (2004). cited by applicant International Search Report and Written Opinion for PCT/EP2019/080753, mailed Mar. 2, 2020. cited by applicant Komisarof, J, et al. “A four gene signature predictive of recurrent prostate cancer,” Oncotarget, 8(2):3430-3440 (2017). cited by applicant Stephenson, AJ, et al. “Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy,” Cancer, 104:290-298 (2005). cited by applicant Sun, Y, et al. “Optimizing molecular signatures for predicting prostate cancer recurrence,” Prostate, 69(10):1119-27 (2009). cited by applicant Ward, JF, et al. “The long-term clinical impact of biochemical recurrence prostate cancer 5 or more years after radical prostatectomy,” J Urol., 170:1872-1876 (2003). cited by applicant Wold, S., et al. “PLS-Regression: A Basic Tool of Chemometrics,” Chemometrics and Intelligent Laboratory Systems, 58, 109-130 (2001). cited by applicant |
| Primary Examiner: | Dauner, Joseph G. |
| Attorney, Agent or Firm: | VIVICAR Law, PLLC |
| رقم الانضمام: | edspgr.12180550 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |